Vol. 1 No. 12 (2021)
Reimbursement Recommendations

Chlormethine Gel (Ledaga)

Published December 10, 2021

Key Messages

  • CADTH recommends that Ledaga should not be reimbursed by public drug plans for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients who have received prior skin-directed therapy.
  • Although evidence from a clinical trial found that Ledaga was not inferior to chlormethine ointment, chlormethine ointment is not used in Canada. There was no evidence to show whether Ledaga works better than or similar to treatments for MF-CTCL that are currently used in Canada.
  • There is an unmet need for treatments with fewer side effects, but it remains unknown whether Ledaga has fewer side effects compared with other treatments for MF-CTCL used in Canada.